StreetAlpha.app
Home › Stocks › VNDA

Vanda Pharmaceuticals Inc. (VNDA)

Healthcare
$3.44
▼ −6.13%
LAST CLOSE · NOV 20

Vanda Pharmaceuticals develops and sells prescription medicines for psychiatric, sleep and neurological conditions. It last closed at $3.44 on Nov 20, down 6.13% on the day. The next earnings report for VNDA is expected around Wed, Feb 10, 2027, after the close. For the quarter ended Sep 2026, VNDA reported EPS of -$0.37 on revenue of $69.8M, with revenue up 24.1% from a year ago. Over its last 8 reports the stock moved an average of 9.0% the session after earnings. Over the last 12 months VNDA insiders bought $38K of stock on the open market and sold $2.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is VNDA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VNDA.

Key Stats

Last 12 months
Results
Revenue
$229.3M
+8.1% vs a year ago
Net income
−$274.8M
−119.9% margin
EPS (diluted)
−$4.62
Free cash flow
−$140.0M
−61.0% margin
Valuation
Market cap
$208.3M
60.5M shares
P/E
–
No P/E while losing money
Price to sales
0.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$61.9M
At Sep 30
Shareholder equity
$199.9M
Shares outstanding
60.5M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $268.7M$268.7MFY2021FY2022: $254.4M$254.4MFY2022FY2023: $192.6M$192.6MFY2023FY2024: $198.8M$198.8MFY2024FY2025: $216.1M$216.1MFY2025

From VNDA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 10
Estimated date · After the close
Reported EPS
-$0.37
Quarter ended Sep 2026
Year ago EPS
-$0.38
Same quarter last year
Revenue
$69.8M
+24.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.50Mar '25Jun 2025: -$0.46Jun '25Sep 2025: -$0.38Sep '25Dec 2025: -$2.39Dec '25Mar 2026: -$0.82Mar '26Jun 2026: -$1.04Jun '26Sep 2026: -$0.37Sep '26Latest -$0.37
Revenue by quarter
Dec 2024: $53.2MDec '24Mar 2025: $50.0MMar '25Jun 2025: $52.6MJun '25Sep 2025: $56.3MSep '25Dec 2025: $57.2MDec '25Mar 2026: $51.7MMar '26Jun 2026: $50.5MJun '26Sep 2026: $69.8MSep '26Latest $69.8M
How VNDA moved after its last 8 reports
Average move the session after a report ±9.0%
Oct 28, 2026After the close+1.3%
Aug 5, 2026After the close+0.5%
May 6, 2026After the close−14.1%
Feb 11, 2026After the close−17.6%
Oct 29, 2025After the close−20.1%
Jul 31, 2025Time not announced−8.8%
May 7, 2025After the close−3.6%
Feb 13, 2025After the close−6.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VNDAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VNDA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VNDA

Technical Analysis

VNDA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 12% below its 20 day and 26% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $3.42, and the nearest resistance the Pivot at $3.56.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.0%/day
Key levels
$9.9452 week high+189.0%
$5.92200 day average+72.1%
$4.89100 day average+42.2%
$4.3450 day average+26.2%
$4.20Swing high (Nov 11)+22.1%
$3.8720 day average+12.5%
$3.70Pivot R1+7.6%
$3.56Pivot+3.5%
$3.44Last close
$3.4252 week low−0.6%
$3.30Pivot S1−4.1%
Indicators
RSI (14)31.80Weak, oversold below 30Neutral
MACD-0.18Below its signal lineBearish
Stochastic16.6Near the bottom of its rangeOversold
ADX (14)23.6Weak trend
Williams %R-96.2Oversold below −80, overbought above −20Oversold
CCI (20)-174.6Oversold below −100, overbought above 100Oversold
Rate of change−9.8%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VNDA

What happened before

See how VNDA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VNDA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VNDA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VNDAHow many large options trades hit VNDA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

VNDA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼63 buying vs 98 selling
  • ▲Held by funds +1.1 pts
  • ▼Funds holding -20
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding152172−11.6%
In funds' top 1001−100.0%
Held by funds83.3%82.2%+1.1 pts
New / increased13 / 5027 / 68−33.7%
Reduced / sold out67 / 3155 / 25+22.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VNDA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VNDA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$38K1 buy · 1 insider
Sold$2.8M6 sales · 6 insiders
2026-02 sold $241K2026-03 sold $2.6M2026-11 bought $38KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 5Charles Cliff DuncanDirectorBuy10,000$3.81$38K
Mar 2Mihael Hristos PolymeropoulosPresident and CEOSale156,235$8.17$1.3M
Mar 2Gunther BirznieksSVP, Business DevelopmentSale42,431$8.27$351K
Mar 2Timothy WilliamsSVP & General CounselSale42,434$8.27$351K
Mar 2Joakim WijkstromSVP, Chief Marketing OfficerSale30,800$8.27$255K
Mar 2Kevin Patrick MoranSVP, CFO & TreasurerSale42,442$8.27$351K
Every insider buy and sale for VNDA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VNDA insider trades →

From SEC Form 4 filings by VNDA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VNDA is in one of them and how their past VNDA trades turned out.

VNDA in the AI portfolios
Loading…

VNDA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VNDA in an article yet. Here's the latest on the wider market.

VNDA in the news

About Vanda Pharmaceuticals

Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, D.C. It develops and sells prescription medicines for patients with psychiatric, sleep and neurological conditions. Its marketed products include Fanapt for schizophrenia and bipolar I disorder, HETLIOZ for certain sleep-wake disorders, PONVORY for multiple sclerosis, and NEREUS for preventing vomiting caused by motion. The company also has other medicines in development.

Headquarters
Washington, DC